by rss feed | Feb 8, 2026 | Casgevy challenge, News Feeds, weekly reads
It was exciting when the combined cell and gene therapies Casgevy and Lyfgenia were approved for sickle cell in late 2023. Still, one of the anticipated challenges was that the therapies could be so expensive that it would limit access. However, since the approval...
